Showing results (331-340 of 358) with videos related to

Sort By:
Pageof 36
Bioinformatics (Oxford, England)|May 10, 2014
SEK: sparsity exploiting k-mer-based estimation of bacterial community compositionSaikat Chatterjee, David Koslicki, Siyuan Dong, et al.
Fuel (London, England)|July 17, 2025
Large-Scale Field Experiments on Enhancing In-Situ Burning with Fire WhirlsWuquan Cui, Joseph L Dowling, Mohammadhadi Hajilou, et al.
DNA Sequence : the Journal of DNA Sequencing and Mapping|July 27, 2007
Novel mutations in the SLC12A3 gene causing Gitelman's syndrome in SwedesCristiano Fava, Martina Montagnana, Lena Rosberg, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|August 18, 2017
Synthesis, Optical Properties, and DNA Interaction of New Diquats Based on Triazolopyridines and TriazoloquinolinesPedro J Llabres-Campaner, Lluís Guijarro, Claudia Giarratano, et al.
Scientific Reports|December 1, 2022
Chemistry and lung toxicity of particulate matter emitted from firearmsYong Ho Kim, Samuel A Vance, Johanna Aurell, et al.
RNA (New York, N.Y.)|March 5, 2015
Whole-genome mapping of 5' RNA ends in bacteria by tagged sequencing: a comprehensive view in Enterococcus faecalisNicolas Innocenti, Monica Golumbeanu, Aymeric Fouquier d'Hérouël, et al.
British Journal of Clinical Pharmacology|June 3, 2024
A drug-drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5-lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolamJane Knöchel, Vijender Panduga, Karin Nelander, et al.
Human Molecular Genetics|November 6, 2007
Subjects heterozygous for genetic loss of function of the thiazide-sensitive cotransporter have reduced blood pressureC Fava, M Montagnana, L Rosberg, et al.
British Journal of Clinical Pharmacology|August 12, 2024
The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstatChandrali S Bhattacharya, Patricia Ely Pizzato, Maria Heijer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 18, 2025
A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non-Cirrhotic Metabolic Dysfunction-Associated SteatohepatitisJavier Armisen, Armando Flor, John Eriksson, et al.
Pageof 36